Switzerland’s Upcoming Cost Containment Packages: Industry…
While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland…
Tagged with Reimbursement
China’s National Reimbursement Drug List (NRDL) 2020: What…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has…
Cross Country Collaborations in Europe: The Future of Pricing…
Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland examines the trend of collaboration between European countries…
Novartis Oncology President: “If We Offer Pay-For-Performance,…
During the FT Global Pharmaceutical and Biotechnology Conference earlier this month, three industry leaders spoke about innovative reimbursement…
Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…
Overcoming US Pricing & Reimbursement Challenges
Executives from ALK, Sanofi Genzyme and Novartis discuss how they are navigating pricing and reimbursement issues in the USA, home to the world’s…
Martin Mátl – Executive Director, ČAFF, Czech Republic
Martin Mátl, executive director of the Czech Association of Pharmaceutical Companies (ČAFF), shares the key priorities and challenges of the…
Mattias Bankel – General Manager, Head of Nordics &…
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.…
Chinese PD-1 Cancer Drugs: Global Competition for Big Pharma
PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began…
Forging a New Path to Commercialization for Cell and Gene…
Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in…
Shooting For the Stars: The Evolution in Outcome-Based Payment…
Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful…
EU Ruling likely to set an increase in off-label use of medicinal…
Managing partner of the law firm Herbert Smith Freehills in Italy, Laura Orlando is one of Italy’s leading life sciences specialists, with a focus…
